{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:30:13Z","timestamp":1696519813314},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s40268-013-0010-z","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T11:26:37Z","timestamp":1364988397000},"page":"95-100","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis"],"prefix":"10.1007","volume":"13","author":[{"given":"Eisuke","family":"Shono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"10_CR1","doi-asserted-by":"crossref","unstructured":"Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17(9 Suppl B):S14\u20138.","DOI":"10.18553\/jmcp.2011.17.s9-b.S14"},{"issue":"5","key":"10_CR2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10_CR3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964\u201375.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10_CR4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/rheumatology\/keq325","volume":"50","author":"W Kievit","year":"2011","unstructured":"Kievit W, Fransen J, Adang EMM, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford). 2011;50(1):196\u2013203.","journal-title":"Rheumatology (Oxford)"},{"issue":"14","key":"10_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15140","volume":"15","author":"K Malottki","year":"2011","unstructured":"Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1\u2013278.","journal-title":"Health Technol Assess"},{"issue":"9","key":"10_CR6","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2010.146043","volume":"70","author":"MU Rahman","year":"2011","unstructured":"Rahman MU, Buchanan J, Doyle MK, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16\u00a0years. Ann Rheum Dis. 2011;70(9):1631\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10_CR7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/art.30263","volume":"63","author":"P Emery","year":"2011","unstructured":"Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011;63(5):1200\u201310.","journal-title":"Arthritis Rheum"},{"key":"10_CR8","doi-asserted-by":"crossref","unstructured":"Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis [Erratum appears in Arthritis Rheum. 2010;62(10):3005]. Arthritis Rheum. 2009;60(8):2272\u201383.","DOI":"10.1002\/art.24638"},{"issue":"6","key":"10_CR9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/ard.2009.116319","volume":"69","author":"E Keystone","year":"2010","unstructured":"Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study [Erratum appears in Ann Rheum Dis. 2011;70(1):238\u20139]. Ann Rheum Dis. 2010;69(6):1129\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10_CR10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study [Erratum appears in Ann Rheum Dis. 2011;70(1):238]. Ann Rheum Dis. 2009;68(6):789\u201396.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10_CR11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","volume":"2","author":"D Shealy","year":"2010","unstructured":"Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010;2(4):428\u201339.","journal-title":"MAbs"},{"issue":"9685","key":"10_CR12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial [Erratum appears in Lancet. 2009;374(9699):1422]. Lancet. 2009;374(9685):210\u201321.","journal-title":"Lancet"},{"issue":"6","key":"10_CR13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2011.200317","volume":"71","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y, Harigai M, Takeuchi T, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012;71(6):817\u201324.","journal-title":"Ann Rheum Dis"},{"key":"10_CR14","unstructured":"Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation. Simponi: Package insert. Japan 2011."},{"issue":"9","key":"10_CR15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"10_CR16","doi-asserted-by":"crossref","unstructured":"Takeuchi T, Harigai M, Tanaka Y, et al. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2\/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24\u00a0weeks. Ann Rheum Dis. Epub 2012 Sep 18.","DOI":"10.1136\/annrheumdis-2012-201796"},{"issue":"6","key":"10_CR17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10165-011-0445-4","volume":"21","author":"Y Seto","year":"2011","unstructured":"Seto Y, Tanaka E, Inoue E, et al. Studies of the efficacy and safety of methotrexate at dosages over 8\u00a0mg\/week using the IORRA cohort database. Mod Rheumatol. 2011;21(6):579\u201393.","journal-title":"Mod Rheumatol"},{"key":"10_CR18","unstructured":"Electronic Medicines Compendium (eMC). Methotrexate 5\u00a0mg tablets: Summary of prescribing information. 2012. http:\/\/www.medicines.org.uk\/emc\/medicine\/22954\/SPC#POSOLOGY . Accessed 2013 Mar 21."},{"issue":"4","key":"10_CR19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2217\/imt.10.34","volume":"2","author":"G Hutas","year":"2010","unstructured":"Hutas G. Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies. Immunotherapy. 2010;2(4):453\u201360.","journal-title":"Immunotherapy"},{"issue":"2","key":"10_CR20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12032-010-9490-7","volume":"28","author":"I Zidi","year":"2011","unstructured":"Zidi I, Bouaziz A, Mnif W, et al. Golimumab and malignancies: true or false association? Med Oncol. 2011;28(2):641\u20138.","journal-title":"Med Oncol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-013-0010-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0010-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0010-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:12:28Z","timestamp":1551204748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-013-0010-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s40268-013-0010-z","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}